Kappa Bioscience 18 Mar 2022 14:24
OSLO, Norway, March 1, 2022 Kappa Bioscience (www.kappabio.com), the leading manufacturer of Vitamin K2 under the brand name K2VITAL® announced today the formation of a "Blue Ribbon" Scientific and Medical Advisory Board to support and expand the scientific knowledge base for Vitamin K2.
The Board reflects Kappa's unique commitment to growing awareness of the rapidly expanding range of benefits associated with Vitamin K2 in the form of Menaquinone 7 (MK-7). It will include world authorities in relevant fields of science, including Cardiology, Immunology, Kinesiology, and Molecular Nutrition, and will set a new standard for the scientific support and advancement of emerging nutritional compounds.
Kappa Bioscience is pleased to announce the current composition of the Advisory Board:
Dr. John Ivy, the Teresa Lozano Long Endowed Chair Emeritus at the University of Texas at Austin. He received his Ph.D. in Exercise Physiology from the University of Maryland and trained in physiology and metabolism at Washington University School of Medicine as an NIH Post-Doctoral Fellow. His research interests include the effect of exercise and nutritional supplementation on physical performance and wellness.
Dr. Susanne Talcott, Associate Professor Texas A&M University, Food Science & Technology, Molecular Researcher. Her research focuses on translational pharmacokinetics and pharmacodynamics of food compounds and their physiological metabolites related to inflammation, cancer prevention, and intestinal health with a focus on human clinical trials.
Dr. Nathan Wong, cardiovascular epidemiologist, a specialist in preventive cardiology, and Professor and Director, Heart Disease Prevention Program, Division of Cardiology at the University of California. He received his Ph.D. degrees in epidemiology from Yale University and his research focuses on the epidemiology of diabetes and cardiovascular disease, subclinical atherosclerosis, and dyslipidemia.
Kappa Bioscience will announce additional members in the immediate future.
"The formation of Kappa's Scientific and Medical Advisory Board is a further demonstration of the Company's commitment to maintaining its leadership position in the K2 sector and to bringing its remarkable health benefits to a growing number of consumers worldwide," stated Egil Greve, Kappa's Chief Executive Officer.
"We are honored to have attracted this esteemed group of scientists. The top-class experts together have authored over 700 scientific papers. We are confident that with their help, awareness of Vitamin K2 and its scope of benefits will rapidly accelerate."
Trygve Bergeland, Ph.D., Vice President Science, will lead the group and coordinate their activities with Kappa's current research initiatives already underway.
Sign In
Follow the stocks
